ArticleEJHaem2026
Sequential Analysis of Murine Myelofibrosis Models Using a Novel Deep Learning-Based Fibrosis Quantitative Method.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications.Biomarker research · 2026Review
- Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement.Journal of cellular physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary myelofibrosis (MF) is characterized by MF, splenomegaly, and extramedullary hematopoiesis. MF initially presents with reticular fibers (RFs) and progresses to increased collagen fiber deposition in the advanced stages. Although recent clinical trials have adopted MF improvement as an evaluation criterion, current diagnostic methods rely primarily on qualitative assessments based on the presence or absence of reticular and collagen fibers. Therefore, detecting subtle changes during the early stages of MF can be challenging. Methods: We developed a novel deep learning-based method for quantitatively evaluating MF by measuring RFs as an indicator. Unlike collagen fibers, RFs are detectable from the early stages of MF and increase as the disease progresses. Moreover, based on the hypothesis that splenic fibrosis progresses in parallel with MF, we applied this method to evaluate RFs in the spleen. Using these methods, we analyzed temporal changes in fibrosis, splenomegaly, and hematopoietic stem cell dynamics over time in two MF models: a drug-induced fibrosis model using romiplostim and a Results: Our findings revealed that in Conclusion: Our novel deep learning-based method successfully captured temporal changes in bone marrow and spleen fibrosis and shows potential for clinical application. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.